The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?
Abstract
The human epidermal growth factor receptor (HER1/EGFR) is dysregulated in many solid tumors, making it an attractive target for anticancer therapy. A number of agents that target this receptor are in use or in development. A specific adverse effect common to this class of agent is a papulopustular rash, usually on the face and upper torso, which generally occurs in a dose-dependent manner. Little is known about the etiology of this rash, and there are no clear evidence-based management recommendations. Histologic data indicate that rash may be caused by HER1/EGFR inhibition in skin, although this has not been confirmed. Findings suggest that there is a relationship between the development of rash and response and/or survival, making rash a potential surrogate marker of activity. Data from multiple studies with cetuximab and erlotinib show a consistent relationship between rash and response, as well as between rash and survival. The relationship between rash and clinical outcome is currently less consistent for gefitinib. Some studies report a correlation, whereas others do not. The cause of the possible relationship between rash and clinical benefit remains unclear at this time, and additional studies are needed to determine the clinical utility of this observation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Self-citationHerbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490
Pérez-Soler, R., Chachoua, A., Hammond, L. A., Rowinsky, E. K., Huberman, M., Karp, D., Rigas, J., Clark, G. M., Santabárbara, P., & Bonomi, P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.057 · Cited by 1,070
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829
Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., & Siu, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.075 · Cited by 807
Ranson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.112 · Cited by 763
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Cohen, E. E. W., Rosen, F., Stadler, W. M., Recant, W., Stenson, K., Huo, D., & Vokes, E. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.051 · Cited by 610
Herbst, R. S., Maddox, A.-M., Rothenberg, M. L., Small, E. J., Rubin, E. H., Baselga, J., Rojo, F., Hong, W. K., Swaisland, H., Averbuch, S. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.038 · Cited by 572
Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J. M., Herbst, R. S., LoRusso, P. M., Rischin, D., Sauleda, S., Gee, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.110 · Cited by 528
Robert, F., Ezekiel, M. P., Spencer, S. A., Meredith, R. F., Bonner, J. A., Khazaeli, M. B., Saleh, M. N., Carey, D., LoBuglio, A. F., Wheeler, R. H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3234 · Cited by 474
Busam, K. J., Capodieci, P., Motzer, R., Kiehn, T., Phelan, D., & Halpern, A. C. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04226.x · Cited by 419
Rowinsky, E. K., Schwartz, G. H., Gollob, J. A., Thompson, J. A., Vogelzang, N. J., Figlin, R., Bukowski, R., Haas, N., Lockbaum, P., Li, Y.-P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.061 · Cited by 329
The EGF Receptor Provides an Essential Survival Signal for SOS-Dependent Skin Tumor Development
Sibilia, M., Fleischmann, A., Behrens, A., Stingl, L., Carroll, J., Watt, F. M., Schlessinger, J., & Wagner, E. F. (2000) · Cell · doi:10.1016/s0092-8674(00)00026-x · Cited by 304
Shepherd, F. A., Pereira, J. R., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Bezjak, A., Tu, D., Santabarbara, P., & Seymour, L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7022 · Cited by 281
Nakagawa, K., Tamura, T., Negoro, S., Kudoh, S., Yamamoto, N., Yamamoto, N., Takeda, K., Swaisland, H., Nakatani, I., Hirose, M., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg250 · Cited by 277
Murillas, R., Larcher, F., Conti, C. J., Santos, M., Ullrich, A., & Jorcano, J. L. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00206.x · Cited by 249
Hansen, L. A., Alexander, N., Hogan, M. E., Sundberg, J. P., Dlugosz, A., Threadgill, D. W., Magnuson, T., & Yuspa, S. H. (1997) · Europe PMC (PubMed Central) · Cited by 239
Kubota, K., Watanabe, K., Kunitoh, H., Noda, K., Ichinose, Y., Katakami, N., Sugiura, T., Kawahara, M., Yokoyama, A., Yokota, S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.114 · Cited by 230
GORDON, A. N., FINKLER, N., EDWARDS, R. P., GARCIA, A. A., CROZIER, M., IRWIN, D. H., & BARRETT, E. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00137.x · Cited by 221
Higgins, B., Kolinsky, K. D., Smith, M. L., Beck, G., Rashed, M., Adames, V., Linn, M., Wheeldon, E. B., Gand, L., Birnboeck, H., et al. (2004) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000127664.66472.60 · Cited by 152
Malik, S. N., Siu, L. L., Rowinsky, E. K., deGraffenried, L. A., Hammond, L. A., Rizzo, J. D., Bacus, S. S., Brattain, M. G., Kreisberg, J. I., & Hidalgo, M. M. (2003) · PubMed · Cited by 130
Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management
Herbst, R. S., LoRusso, P. M., Purdom, M., & Ward, D. A. (2003) · Clinical Lung Cancer · doi:10.3816/clc.2003.n.016 · Cited by 119
Gore, M. E., Oza, A. M., Rustin, G. J. S., Malfetano, J. H., Calvert, H., Clarke‐Pearson, D. L., Carmichael, J., Ross, G. A., Beckman, R., & Fields, S. Z. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00188-5 · Cited by 106
Anti-epidermal growth factor receptor drugs in cancer therapy
Tortora, G., & Ciardiello, F. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.6.755 · Cited by 104
King, L. E., Gates, R. E., Stoscheck, C. M., & Nanney, L. B. (1990) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12876141 · Cited by 90
Kimyai‐Asadi, A., & Jih, M. H. (2002) · Archives of Dermatology · doi:10.1001/archderm.138.1.129 · Cited by 89
Fisher, G. A., Kuo, T., Cho-Phan, C. D., Halsey, J., Jambalos, C. N., Schwartz, E., Rouse, R. V., Advani, R. H., & Wakelee, H. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3514 · Cited by 89
Karp, D. D., Ferrante, K. J., Tensfeldt, T. G., Thurer, R. L., LoCicero, J., Huberman, M. S., Wirth, F., Hellman, R., Poulin, P., Silberman, S., et al. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)80208-1 · Cited by 58
Uncommon Presentations of Hodgkin's Disease: CASE 3. Hodgkin's Disease: Rectal Presentation
Simpson, L., Taylor, S. G., & Piotrowski, A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.144 · Cited by 58
Ochs, J., Grous, J. J., & Warner, K. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7060 · Cited by 31
Newlands, E. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.242 · Cited by 29
Perez, E. A., Suman, V. J., Davidson, N. E., Martino, S., Kaufman, P. A., Lingle, W. L., Flynn, P. J., Ingle, J. N., Visscher, D. W., & Jenkins, R. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.567 · Cited by 20
Coyne, J. C., Palmer, S. C., & Shapiro, P. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.221 · Cited by 12
Modulation of tumor growth and survival pathways in cancer patients treated with GW572016
Spector, N. L., Xia, W., Burris, H. A., Hurwitz, H. I., Dees, C., Dowlati, A., McKay, C., Koch, K., Harris, J., & Bacus, S. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3003 · Cited by 10
Cited by
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
“There is incomplete evidence that the strength of skin rash may be a good indication of drug activity and possibly favorable patient response and survival (Perez-Soler and Saltz, 2005).”
BackgroundVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
Metadata
- Authors
- Peréz-Soler, R., & Saltz, L.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-08-01
- Volume
- 23
- Issue
- 22
- Pages
- 5235-5246
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1968151389
- Cited by
- 486
- References
- 44
- FWCI
- 62.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.